Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02684578 · ClinicalTrials.gov registry record · Phase 2
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT02684578 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 66 participants.
The verdict
NCT02684578, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).
Interventions
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2016-04 |
| Est. Completion | 2022-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02684578
The ClinicalTrials.gov registry entry for NCT02684578 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metformin is the first listed.
NCT02684578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02684578 about?
NCT02684578 is a clinical study titled "Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD". The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).
What is the current status of trial NCT02684578?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2016-04. Estimated completion is 2022-10.
What interventions are being tested in trial NCT02684578?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT02684578?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.